Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event

Reuters

21 Jul

Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event

Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&D Day event, where the company will review its advanced central nervous system $(CNS)$ pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2553947962"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553947962\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553947962?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-21 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553947962","market":"us","top_or_hot":-1,"title":"Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&amp;D Day Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&amp;D Day event, where the company will review its advanced central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-21 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&amp;D Day Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&amp;D Day event, where the company will review its advanced central nervous system <a href=\"https://laohu8.com/S/CNS\">$(CNS)$</a> pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL4X4v8g:1","article_id":"2553947962","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553947962","pubTimestamp":1753097426,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&D Day event, where the company will review its advanced central nervous system  pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4505":"高瓴资本持仓","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","AXSM":"Axsome Therapeutics, Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"Axsome Therapeutics在研发日活动中公布了AXS-05治疗阿尔茨海默氏焦虑症的有希望的3期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9,"NDAQ":0.9},"content_text":"Axsome Therapeutics Unveils Promising Phase 3 Trial Results for AXS-05 in Alzheimer's Agitation at R&D Day Event\n    \n\n        Axsome Therapeutics Inc. has announced its Frontiers in Brain Health R&D Day event, where the company will review its advanced central nervous system $(CNS)$ pipeline. The event will feature presentations from expert clinicians and key opinion leaders on conditions such as Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Notably, Dr. Jeffrey Cummings will discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 for Alzheimer's disease agitation, and Dr. Andrea Chadwick will review the Phase 2 and Phase 3 clinical trials of AXS-14 for fibromyalgia. The company will webcast the event, making it accessible to institutional investors, sell-side analysts, and the public via its website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497487-en) on July 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}